Psilocin prodrug receives USPTO development approval [Psychedelic Health]
Thursday, November 2, 2023 1 min read
Key Takeaway: Enveric Biosciences has secured a Notice of Allowance from the USPTO for its patent application related to EB-373, a prodrug of psilocin. This development marks a significant step for the company in the psychedelic health sector. The approval may strengthen Enveric's market position and innovation in this emerging field.
Market Sentiment Analysis
POSITIVE FACTORS
Enveric Biosciences received a Notice of Allowance from the USPTO.
The patent application is for EB-373, a new chemical entity.
This approval could enhance the company's position in psychedelic health.
Full Press Release Details
Enveric Biosciences has received a Notice of Allowance (NoA) from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, the company’s new chemical entity (NCE) prodrug of psilocin.
Full Article
Frequently Asked Questions
What is EB-373?
EB-373 is a new chemical entity prodrug of psilocin developed by Enveric Biosciences.
What approval did Enveric Biosciences receive?
Enveric Biosciences received a Notice of Allowance from the USPTO for EB-373.
Why is the USPTO approval significant?
The USPTO approval is significant as it strengthens Enveric's position in the psychedelic health market.